Recent advances in nanotechnology for Parkinson’s disease: diagnosis, treatment, and future perspectives
Frontiers in Medicine,
Journal Year:
2025,
Volume and Issue:
12
Published: Jan. 22, 2025
Parkinson’s
disease
is
a
progressive
neurodegenerative
that
destroys
substantia
nigra
dopaminergic
neurons,
causing
tremors,
bradykinesia,
rigidity,
and
postural
instability.
Current
treatment
approaches
primarily
focus
on
symptom
management,
employing
pharmacological,
non-pharmacological,
surgical
methods.
However,
these
treatments
often
result
in
fluctuating
symptoms,
side
effects,
progression.
Here,
the
authors
have
reviewed
emerging
field
of
nanomedicine
as
promising
path
for
treatment,
emphasizing
its
potential
to
overcome
limitations
traditional
therapies.
Nanomedicine
utilizes
nanoparticles
targeted
drug
delivery,
leveraging
their
small
size
high
surface
area
volume
ratio
cross
blood-brain
barrier
deliver
therapeutic
agents
directly
affected
brain
regions.
Various
nanoparticles,
including
lipid-based,
polymeric,
metallic,
carbon-based,
shown
treatment.
Additionally,
nanocarrier
systems
like
liposomes,
nanogels,
dendrimers,
solid
lipid
offer
controlled
sustained
release
agents,
enhancing
bioavailability
reducing
effects.
This
review
provides
insights
into
pathophysiology
disease,
highlighting
mechanisms
neurodegeneration,
role
alpha-synuclein,
disruption
pathways.
It
further
discusses
application
gene
therapy
conjunction
with
interventions.
Language: Английский
Managing cognitive impairment in Parkinson’s disease: an update of the literature
Expert Review of Neurotherapeutics,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 21
Published: Jan. 7, 2025
Introduction
Cognitive
impairment
in
Parkinson's
disease
(PD)
substantially
affects
patient
outcomes,
function,
and
quality
of
life.
PD-related
cognitive
dysfunction
is
often
heterogeneous
clinical
presentation
rates
progression.
As
changes
occur
many
people
with
PD,
it
essential
to
evaluate
cognition,
provide
education,
implement
management
strategies
for
symptoms.
Language: Английский
Parkinson's Disease: Insights into Epidemiology, Experimental Models, and Novel Therapeutic Approaches
M. R. C. P.,
No information about this author
D R,
No information about this author
F M
No information about this author
et al.
International Journal of Allied Medical Sciences and Clinical Research,
Journal Year:
2025,
Volume and Issue:
13(1), P. 100 - 111
Published: March 29, 2025
Parkinson’s
disease
(PD)
is
a
progressive
neurodegenerative
disorder
that
primarily
affects
motor
functions,
with
symptoms
such
as
tremors,
bradykinesia,
rigidity,
and
postural
instability.
Non-motor
symptoms,
including
cognitive
impairment
mood
disorders,
also
contribute
to
the
burden.
While
exact
etiology
remains
unclear,
both
genetic
environmental
factors
play
role
in
its
onset
progression.
The
prevalence
of
PD
increasing,
particularly
among
aging
populations,
men
being
more
affected
than
women.
Various
experimental
models,
chemically
induced
animal
are
used
study
pathophysiology
evaluate
potential
treatments.
Current
therapeutic
approaches
focus
on
symptom
management
through
pharmacological
treatments
levodopa,
dopamine
agonists,
MAO-B
inhibitors,
well
non-pharmacological
interventions
like
physiotherapy,
therapy,
deep
brain
stimulation
(DBS).
Despite
advancements
understanding
PD,
no
cure
exists,
research
continues
explore
disease-modifying
early
diagnostic
methods.
This
review
highlights
key
epidemiological
trends,
research,
current
strategies,
emphasizing
need
for
multidisciplinary
improve
patient
outcomes
quality
life.
Language: Английский
Development, Reliability, and Validity of the Telerehabilitation Usability Questionnaire in Neurological Diseases
Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi,
Journal Year:
2025,
Volume and Issue:
14(1), P. 124 - 132
Published: March 23, 2025
The
purpose
was
to
develop
Telerehabilitation
Usability
Questionnaire
(TrUQ)
and
evaluate
its
validity
reliability
in
neurological
diseases.
Ninety-five
people
with
Multiple
Sclerosis,
stroke,
Parkinson’s
disease
participated
this
study.
Content
assessed
by
an
expert
panel
of
5
physiotherapist
experienced
telerehabilitation.
Construct
investigated
using
Confirmatory
Factor
Analysis
(CFA)
Explanatory
(EFA).
Test-retest
Internal
consistency
were
used
the
TrUQ.
A
three-factor
structure
determined
based
on
EFA.
Accordingly,
three
factors
correspond
subscales,
TrUQ:
system
availability,
exercise
feasibility,
telerehabilitation
security.
Furthermore,
model
fits
well
according
CFA
results:
χ²/df
=
1.573,
CFI
0.925,
IFI
0.929,
GFI
0.909,
RMSEA
0.078.
questionnaire
proven
have
acceptable
level
(Cronbach’s
alpha=
0.712)
it
found
that
all
items
necessary.
Finally,
a
10-item
version
obtained,
TrUQ
shown
test–retest
(ICC=645)
is
valid
reliable
can
be
measure
usability
systems
Adaptation
different
languages
diseases
recommended
widely
applicable.
Language: Английский
Sex Differences in Parkinson’s Disease: A Narrative Review
Neurology and Therapy,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 4, 2024
Sex
differences
in
epidemiology,
clinical
features,
and
therapeutical
responses
are
emerging
several
movement
disorders,
even
though
they
still
not
widely
recognized.
Parkinson's
disease
(PD)
is
an
exception:
men
women
suffering
from
PD
have
different
levels
of
disability.
Research
has
been
performed
using
multiple
databases
scientific
journals;
this
review
summarizes
the
available
evidence
on
sex
regarding
risk
factors,
genetics,
phenotype,
social
impact,
therapeutic
management.
The
role
hormones
determining
such
also
briefly
discussed.
results
confirm
existence
between
PD;
a
higher
developing
disabling
motor
complications
non-motor
fluctuations
compared
to
men,
while
cognitive
impairment,
postural
instability,
gait
disorders.
Improving
our
knowledge
these
may
result
implementation
strategies
for
disease-tailored
treatment
Language: Английский